Aligos reports FY2022 net loss of $96M; provides pipeline updates for NASH, COVID-19, HBV

Aligos Therapeutics, Inc.

Net loss FY2022 $96.0M ($2.25/share) vs $128.3M ($3.22) in FY2021; cash $125.8M as of Dec 31, 2022.
NASH candidate ALG-055009 Phase 1 data positive; on track for Phase 2 filing by end 2023.
COVID-19 candidate ALG-097558 to enter clinic in Q2 2023; top line data expected Q4 2023.
HBV CAM-E ALG-000184 shows HBsAg reductions; 48-week data expected in 2023.
HBV siRNA ALG-125755 SAD in healthy volunteers completed; now evaluating in CHB subjects.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Aligos Therapeutics, Inc. reported the fourth quarter and full year 2022 results: net income Net losses for the three months ended December 31, 2022, were $21.9 million or basic and diluted net loss per common sha, EPS $(0.51).

Period: the fourth quarter and full year 2022
Net income: Net losses for the three months ended December 31, 2022, were $21.9 million or basic and diluted net loss per common sha
EPS: $(0.51)
Result: reported results

Exact text from the filing

Net losses for the three months ended December 31, 2022, were $21.9 million or basic and diluted net loss per common share of $(0.51), compared to net losses of $37.7 million or basic and diluted net loss per common share of $(0.89) for the three months ended December 31, 2021. Net losses for the year ended December 31, 2022, were $96.0 million or basic and diluted net loss per common share of $(2.25), compared to net losses of $128.3 million or basic and diluted net loss per common share of $(3.22) for the year ended December 31, 2021.

View on SEC.gov

Browse all earnings releases →

Aligos Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001171843-23-001548

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.